Septal Ablation Versus Surgical Myomectomy for Hypertrophic Obstructive Cardiomyopathy.

Alcohol septal ablation Gradient Hypertrophic cardiomyopathy Left ventricular outflow tract Myectomy Obstruction

Journal

Current cardiology reports
ISSN: 1534-3170
Titre abrégé: Curr Cardiol Rep
Pays: United States
ID NLM: 100888969

Informations de publication

Date de publication:
01 10 2021
Historique:
accepted: 13 07 2021
entrez: 2 10 2021
pubmed: 3 10 2021
medline: 24 10 2021
Statut: epublish

Résumé

Patients with hypertrophic cardiomyopathy (HCM) who have left ventricular outflow tract obstruction (LVOTO) often experience severe symptoms and functional limitation. Relief of LVOTO can be achieved by two invasive interventions, i.e., surgery myectomy and alcohol septal ablation (ASA), leading in experienced hands to a dramatic improvement in clinical status. Despite extensive research, however, the choice of the best option in individual patients remains challenging and poses numerous clinical dilemmas. Invasive strategies have been recently incorporated in recommendations for the diagnosis and treatment of HCM on both sides of the Atlantic. These guidelines are based on a bulk of well-designed but retrospective studies as well as on expert opinions. Evidence now exists that adequate evaluation and management of HCM requires a multidisciplinary team capable of choosing the best available options. Management of LVOTO still varies largely based on local expertise and patient preference. Following the trend that has emerged for other cardiac diseases amenable to invasive interventions, the concept of a "HCM heart team" is coming of age.

Identifiants

pubmed: 34599387
doi: 10.1007/s11886-021-01600-5
pii: 10.1007/s11886-021-01600-5
pmc: PMC8486700
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

165

Informations de copyright

© 2021. The Author(s).

Références

Lancet. 2017 Mar 25;389(10075):1253-1267
pubmed: 27912983
Heart Lung. 2003 Nov-Dec;32(6):402-6
pubmed: 14652532
Int J Cardiol. 2019 Jul 1;286:239-243
pubmed: 30409740
Int J Cardiol. 2017 Sep 15;243:379-384
pubmed: 28747036
Lancet. 1995 Jul 22;346(8969):211-4
pubmed: 7616800
Am J Cardiol. 2019 May 1;123(9):1517-1526
pubmed: 30791998
Circulation. 1962 Sep;26:325-40
pubmed: 14006898
Eur Heart J. 2016 May 14;37(19):1517-23
pubmed: 26746632
Ann Cardiothorac Surg. 2017 Jul;6(4):307-317
pubmed: 28944171
J Am Coll Cardiol. 2018 Dec 18;72(24):3087-3094
pubmed: 30545446
Circulation. 2006 Nov 21;114(21):2232-9
pubmed: 17088454
J Am Coll Cardiol. 2015 Oct 13;66(15):1687-96
pubmed: 26449139
J Am Coll Cardiol. 2007 Aug 28;50(9):831-4
pubmed: 17719467
Circ Res. 2017 Sep 15;121(7):749-770
pubmed: 28912181
Circulation. 1964 Mar;29:422-31
pubmed: 14128830
Circulation. 1964 Nov;30:SUPPL 4:120-51
pubmed: 14227304
J Thorac Cardiovasc Surg. 2018 Aug;156(2):710
pubmed: 30011761
Gen Thorac Cardiovasc Surg. 2018 Apr;66(4):243-245
pubmed: 28825167
EuroIntervention. 2019 Aug 29;15(5):411-417
pubmed: 30860070
Circulation. 1998 Dec 1;98(22):2415-21
pubmed: 9832486
Circulation. 1995 Feb 15;91(4):1189-95
pubmed: 7850958
Int J Cardiol. 2020 Apr 1;304:86-92
pubmed: 31983465
Circ Res. 2017 Sep 15;121(7):771-783
pubmed: 28912182
JACC Heart Fail. 2015 Nov;3(11):896-905
pubmed: 26454847
Eur Heart J. 2014 Oct 14;35(39):2733-79
pubmed: 25173338
N Engl J Med. 2018 Nov 15;379(20):1977
pubmed: 30428294
J Am Coll Cardiol. 2019 Aug 6;74(5):645-655
pubmed: 31370956
J Am Coll Cardiol. 2020 Dec 22;76(25):e159-e240
pubmed: 33229116
Am J Cardiol. 2014 Nov 1;114(9):1390-5
pubmed: 25205630
Int J Cardiol. 2021 May 15;331:174-175
pubmed: 33524466

Auteurs

F Pelliccia (F)

Department of Cardiovascular Sciences, University Sapienza, Via del Policlinico 155, 00161, Rome, Italy. f.pelliccia@mclink.it.

H Seggewiss (H)

Comprehensive Heart Failure Center (CHFC), Deutsches Zentrum Für Herzinsuffizienz (DZHI), Universitätsklinikum Würzburg, Würzburg, Germany.

F Cecchi (F)

Department of Cardiovascular, Neural and Metabolic Sciences, IRCCS Istituto Auxologico Italiano, San Luca Hospital, Milan, Italy.

P Calabrò (P)

Department of Translational Medical Sciences, University of Campania 'Luigi Vanvitelli', Naples, Italy.

G Limongelli (G)

Department of Translational Medical Sciences, University of Campania 'Luigi Vanvitelli', Naples, Italy.
Institute of Cardiovascular Sciences, University College of London, St. Bartholomew's Hospital, London, UK.

O Alfieri (O)

Department of Cardiovascular and Thoracic Surgery, San Raffaele University Hospital, Milan, Italy.

P Ferrazzi (P)

Hypertrophic Cardiomyopathy Center, Policlinico Di Monza, Monza, Italy.

M H Yacoub (MH)

Heart Science Centre, National Heart and Lung Institute, Imperial College London, London, UK.

I Olivotto (I)

Cardiomyopathy Unit, Careggi University Hospital, Florence, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH